Presentation Type: Speech
Abstract: Currently, there are several commercially available multigenomic tests that can be used for decision-making concerning adjuvant chemotherapy of patients with breast cancer. These tests include Oncotype Dx, MammaPrint, Prosigna (PAM 50), and EndoPredict. While all these available tests have a high sensitivity and high negative predictive value, they suffer significantly from low specificity and low positive predictive value. During the presentation, advantages and limitations of each test will be critically reviewed. A practical approach in dealing with the use of a multigenomic test will be provided.